These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38061684)
1. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations. Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684 [TBL] [Abstract][Full Text] [Related]
2. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
3. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350 [TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
5. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related]
6. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830 [TBL] [Abstract][Full Text] [Related]
7. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005 [TBL] [Abstract][Full Text] [Related]
8. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
9. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003 [TBL] [Abstract][Full Text] [Related]
10. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809 [TBL] [Abstract][Full Text] [Related]
11. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
12. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
13. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
15. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465 [TBL] [Abstract][Full Text] [Related]
16. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145 [TBL] [Abstract][Full Text] [Related]
17. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related]
18. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing. Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196 [TBL] [Abstract][Full Text] [Related]
19. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
20. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]